I found this on the Info Link. prostatecancerinfolink.net/2013/06/19/parp-inhibition-tmprss2-epg-gene-fusion-and-veliparib-in-mcrpc/
They say here that the clinical trial is the first known that targets this specific gene-subset to a prostate cancer drug therapy.
I'm in a trial in New Jersey involving ABT-888 and BRCA2 and so far my PSA has gone down from 17 to 4. At this point, it may even be lower. My oncologist optimistically says that it could last for "years and years." Let's hope!
Note: This form of therapy is only applicable to men who have certain genetic mutations.
Good luck to all pathways involving genetics!
Diagnosed 9/14/2011; Age 47; PSA 5,000+
Metastatic Stage 4, spread to entire skeleton w/femur fracture
Current therapy: Lupron/Casodex/Aredia
6/4/12: PSA 2.2
6/27/12: PSA 1.42
7/24/12: PSA 0.69
9/25/12: PSA 1.2
10/11/12 PSA 1.4
10/10/12 PSA 3.79 (starting tripling Casodex dosage)
1/14/13 PSA 2.88
3/11/13 PSA 6.35 (time for Xtandi?)
5/3/13 PSA 17 (started ABT-888)